Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted equity awards to four new employees. The grants include options to purchase 14,100 shares of common stock at an exercise price of $17.85 per share, which was the closing price on November 8, 2024. Additionally, the employees received restricted stock units to acquire 7,050 shares. These equity awards were granted under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.
Arcus Biosciences (NYSE:RCUS) ha annunciato che il suo Comitato per la Retribuzione ha concesso premi azionari a quattro nuovi dipendenti. I premi includono opzioni per acquistare 14.100 azioni ordinarie a un prezzo di esercizio di 17,85 dollari per azione, che corrisponde al prezzo di chiusura dell'8 novembre 2024. Inoltre, i dipendenti hanno ricevuto unità di azioni ristrette per acquisire 7.050 azioni. Questi premi azionari sono stati concessi nell'ambito del Piano di Induzione 2020 della Società, approvato dal Consiglio di Amministrazione nel gennaio 2020 ai sensi della 'eccezione di induzione' della Regola 303A.08 del Manuale delle Aziende quotate NYSE.
Arcus Biosciences (NYSE:RCUS) anunció que su Comité de Compensación otorgó premios en acciones a cuatro nuevos empleados. Las concesiones incluyen opciones para comprar 14,100 acciones ordinarias a un precio de ejercicio de $17.85 por acción, que fue el precio de cierre del 8 de noviembre de 2024. Además, los empleados recibieron unidades de acciones restringidas para adquirir 7,050 acciones. Estos premios en acciones fueron otorgados bajo el Plan de Inducción 2020 de la Compañía, aprobado por la Junta Directiva en enero de 2020 bajo la 'excepción de inducción' de la Regla 303A.08 del Manual de Empresas Listadas de NYSE.
Arcus Biosciences (NYSE:RCUS)는 보상 위원회가 네 명의 신입 직원에게 주식 관련 보상을 부여했다고 발표했습니다. 보상에는 14,100주를 $17.85의 행사가로 구매할 수 있는 옵션이 포함되어 있으며, 이는 2024년 11월 8일의 종가입니다. 또한 직원들은 7,050주를 취득하기 위한 제한 주식 단위를 받았습니다. 이러한 주식 보상은 2020년 1월 이사회에 의해 승인된 회사의 2020 유도 계획에 따라 부여되었습니다. 이는 NYSE 상장 회사 매뉴얼 규칙 303A.08의 '유도 예외'에 해당합니다.
Arcus Biosciences (NYSE:RCUS) a annoncé que son Comité de Rémunération a accordé des attributions d'actions à quatre nouveaux employés. Ces attributions comprennent des options pour acheter 14 100 actions ordinaires à un prix d'exercice de 17,85 $ par action, correspondant au prix de clôture du 8 novembre 2024. De plus, les employés ont reçu des unités d'actions restreintes leur permettant d'acquérir 7 050 actions. Ces attributions d'actions ont été accordées dans le cadre du Plan d'Incitation 2020 de la Société, approuvé par le Conseil d'administration en janvier 2020 conformément à l'‘exception d'incitation’ de la règle 303A.08 du Manuel des Sociétés Côtées de la NYSE.
Arcus Biosciences (NYSE:RCUS) gab bekannt, dass sein Vergütungsausschuss an vier neue Mitarbeiter Aktienoptionen verliehen hat. Die Optionen umfassen die Möglichkeit, 14.100 Stammaktien zu einem Ausübungspreis von 17,85 $ pro Aktie zu erwerben, was dem Schlusskurs vom 8. November 2024 entspricht. Zusätzlich erhielten die Mitarbeiter beschränkte Aktienanteile zur Erwerbung von 7.050 Aktien. Diese Aktienoptionen wurden im Rahmen des Induktionsplans der Gesellschaft 2020 vergeben, der im Januar 2020 vom Vorstand gemäß der 'Induktionsausnahme' der Regel 303A.08 des NYSE-Listings genehmigt wurde.
- None.
- None.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112122759/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
How many shares were granted in Arcus Biosciences (RCUS) November 2024 inducement grants?
What was the exercise price for RCUS stock options granted on November 8, 2024?
Under which plan were the RCUS November 2024 equity awards granted?
